Market Overview

Pfizer Confirms License of Families of Spinal Muscular Atrophy Quinazoline Drug Program from Repligen

Share:
Related RGEN
A Peek Into The Markets: U.S. Stock Futures Mostly Lower Ahead Of Fed Speakers, Economic Data
PreMarket Prep Recap, March 20: Major Volatility At Friday's Close And Why Disney Is In For A Big Quarter
Related PFE
Cramer's Guide To Profit From Market Rotations
The Street Has Finally Recognized The Exelixis Clinical Program Potential

Repligen Corporation (NASDAQ: RGEN) announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. (NYSE: PFE) to advance Repligen's spinal muscular atrophy (SMA) program, originally in-licensed from Families of SMA (FSMA).

Posted-In: News FDA

 

Related Articles (RGEN + PFE)

View Comments and Join the Discussion!
Loading...
Loading...